Herranz J L, Argumosa A
Universidad de Cantabria, Servicion de Neuropediatría Hospital Universitario Marqués de Valdecilla. Santander, España.
Rev Neurol. 2002 Sep;35 Suppl 1:S101-9.
To review the major studies published concerning the pharmacokinetic characteristics, mechanism of action, clinical efficacy and adverse effects of oxcarbazepine (OXC).
OXC is a ketoderivative of carbamazepine (CBZ), with a similar mechanism of action, possibly widening the voltage dependent potassium channels. Its pharmacokinetic characteristics are much better than those CBZ but the frequency and intensity of interactions is much less. In several double blind trials, using the drug in monotherapy in previously untreated patients, similar efficacy was found after OXC, phenytoin, valproate and CBZ but the fewest adverse effects were seen after OXC.
OXC is an antiepileptic drug with better pharmacokinetic properties than CBZ and similar clinical efficacy, but better tolerated, so it may therefore be expected to replace this classical antiepileptic drug for use in monotherapy and polytherapy of both children and adults in all types of partial seizures.
综述已发表的有关奥卡西平（OXC）药代动力学特征、作用机制、临床疗效及不良反应的主要研究。
奥卡西平是卡马西平（CBZ）的酮衍生物，作用机制相似，可能是通过拓宽电压依赖性钾通道发挥作用。其药代动力学特征比卡马西平好得多，但相互作用的频率和强度要低得多。在多项双盲试验中，对既往未治疗的患者使用该药物进行单药治疗，结果发现奥卡西平、苯妥英、丙戊酸盐和卡马西平的疗效相似，但奥卡西平的不良反应最少。
奥卡西平是一种抗癫痫药物，其药代动力学特性优于卡马西平，临床疗效相似，但耐受性更好，因此有望取代这种经典抗癫痫药物，用于儿童和成人各类部分性发作的单药治疗和联合治疗。
